{"entity":{"id":"leukemia","kind":"journal","name":"Leukemia","aka":["Leukemia (Springer Nature)"],"tldr":"Leukemia is a Springer Nature haematology journal covering leukaemia, lymphoma and myeloma biology and clinical research, including the International Myeloma Working Group consensus papers.","summary":"Leukemia is a Springer Nature haematology journal, founded in 1987, appearing monthly and published on a hybrid access model. It covers leukaemia, lymphoma and myeloma biology and clinical research, publishing genomic and clonal-evolution studies of leukaemia, myeloma and MDS, phase 2 trials and long-term follow-up, and the International Myeloma Working Group and European LeukemiaNet consensus and response criteria. Its readers are haematologists and translational researchers in blood cancers who need the consensus definitions that trials are built on. Within OnCo it is linked from the Katayoun Rezvani biography, and it is where a reader would look for myeloma and leukaemia consensus papers and clonal-evolution studies.","asOf":"2026-09-09","links":[{"label":"Springer Nature","url":"https://www.springernature.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["leukaemia-type","interim-analysis"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/leu/","issn":"0887-6924","scope":"haematology","access":"hybrid","founded":1987,"impactFactor":{"value":12.8,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Leukemia"]},"route":"/journals/leukemia/","neighbours":{"term":[{"id":"interim-analysis","kind":"term","name":"Interim analysis, readout and data cut-off","route":"/terms/interim-analysis/"},{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/"}],"person":[{"id":"biju-george","kind":"person","name":"Biju George","route":"/people/biju-george/"},{"id":"katy-rezvani","kind":"person","name":"Katayoun Rezvani","route":"/people/katy-rezvani/"},{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","route":"/people/thomas-loughran/"}],"paper":[{"id":"paper-bcma-multiple-myeloma-leukemia-2020","kind":"paper","name":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","route":"/key-papers/paper-bcma-multiple-myeloma-leukemia-2020/"},{"id":"paper-eln-2020-cml-hochhaus-leukemia-2020","kind":"paper","name":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia","route":"/key-papers/paper-eln-2020-cml-hochhaus-leukemia-2020/"},{"id":"paper-ferreri-leukemia","kind":"paper","name":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","route":"/key-papers/paper-ferreri-leukemia/"},{"id":"paper-jak2-myeloproliferative-neoplasms-leukemia-2010","kind":"paper","name":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","route":"/key-papers/paper-jak2-myeloproliferative-neoplasms-leukemia-2010/"},{"id":"paper-who-2022-lymphoid-alaggio-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms","route":"/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/"},{"id":"paper-who-2022-myeloid-khoury-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms","route":"/key-papers/paper-who-2022-myeloid-khoury-leukemia-2022/"}]}}